Department of Trauma and Orthopaedics, Royal Liverpool and Broadgreen Hospital, Liverpool, United Kingdom.
J Arthroplasty. 2017 Dec;32(12):3685-3688. doi: 10.1016/j.arth.2017.07.015. Epub 2017 Jul 20.
Blood cobalt (Co) and chromium (Cr) ion levels have been used as surveillance tools for adverse reaction to metal debris (ARMD) in metal-on-metal (MoM) articulations with varying thresholds in different countries. The aim of our study is to present the serial 12-year blood Co and Cr levels in a cohort of MoM total hip arthroplasties (THAs) with femoral head size ≥36 mm and analyze their utility in asymptomatic patients at current thresholds.
A total of 256 patients with unilateral MoM THA with femoral head size ≥36 mm were included in this study with data collected prospectively. The implants used were Birmingham hip resurfacing cup-Freeman stem (BHR-F) or an Articular Surface Resurfacing cup-Corail/S-ROM stem. Annual follow-up with blood Co and Cr measurements was done as per Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom guidelines. Receiver operating characteristic curve was plotted based on the sensitivity and specificity of blood metal ion values to detect ARMD. The metal ion levels in asymptomatic patients were analyzed separately.
Receiver operating characteristic curves showed poor discriminatory ability for both Co and Cr values in predicting ARMD at 7 μg/L. The sensitivity of Co and Cr was 82.1% and 53.5%, respectively, and their positive predictive values were 43.8% and 67.6%, respectively. After 7 years, there was no significant change in Co values, and there was a decline in Cr value after 9 years in asymptomatic patients.
To the best of our knowledge, this is the first study to describe the behavior of serial blood metal ion levels in asymptomatic large-diameter MoM THA. We suggest that annual blood Co and Cr have limited discriminant capacity in diagnosing the occurrence of metallosis and their measurement beyond 7 years is of limited utility in asymptomatic patients.
血钴(Co)和铬(Cr)离子水平已被用作监测金属对金属(MoM)关节中金属碎屑不良反应(ARMD)的工具,不同国家有不同的阈值。我们研究的目的是展示一组直径大于 36mm 的 MoM 全髋关节置换术(THA)患者的 12 年连续血 Co 和 Cr 水平,并分析其在当前阈值下无症状患者中的应用价值。
本研究共纳入 256 例单侧直径大于 36mm 的 MoM THR 患者,前瞻性收集数据。使用的植入物为 Birmingham 髋关节表面置换杯-Freeman 柄(BHR-F)或关节表面置换杯-Corail/S-ROM 柄。根据英国药品和保健产品监管局(MHRA)的指南,每年进行一次随访,检测血 Co 和 Cr 水平。根据血金属离子值检测 ARMD 的灵敏度和特异性绘制受试者工作特征曲线。分析无症状患者的金属离子水平。
受试者工作特征曲线显示 Co 和 Cr 值在预测 7μg/L 时对 ARMD 的鉴别能力较差。Co 和 Cr 的灵敏度分别为 82.1%和 53.5%,阳性预测值分别为 43.8%和 67.6%。7 年后 Co 值无明显变化,9 年后无症状患者 Cr 值下降。
据我们所知,这是第一项描述无症状大直径 MoM THR 患者连续血金属离子水平变化的研究。我们建议,每年检测血 Co 和 Cr 对诊断金属沉着症的发生能力有限,在无症状患者中测量超过 7 年的价值有限。